Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2020 Oct 9;20(1):150–160. doi: 10.1158/1535-7163.MCT-19-0911

Figure 2. Effect of Hsp90 inhibition on primary PSC/CAF and normal pancreatic fibroblasts.

Figure 2.

Treatment of primary PDAC patient-derived PSC/CAF (SC37) or normal human pancreatic fibroblasts (HPF) with XL888 were analyzed by MTT assay (A and C) following a 72 hour treatment or immunoblot analysis (B and D) following a 48 hour treatment. β-actin served as a loading control *denotes p<0.05. (E) Analysis of Trypan Blue staining of PBMCs from normal donors following a 48 hour treatment with XL888. Error bars represent standard deviation of n=3 biologic replicates.